Report Overview

The US Breast cancer drugs market size stood at USD 6.8 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Rising prevalence of breast cancer pertaining to factors such as prolonged exposure to endogenous oestrogens, early menarche, late age at first childbirth and late menopause will be a high impact rendering factor for the industry growth. Increasing technological advances in cancer biology and launch of several diagnostic and screening programs worldwide should drive the business size. Growing adoption of therapeutics owing to factors such as blocking estrogenic from binding to tumour cells, risk of distant reappearance, lowering jeopardy of reappearance in the breast that had tumour and reducing risk of developing disease in another breast will propel the industry growth



Market Drivers

Growing awareness regarding breast cancer, rising shift towards adoption of western lifestyle, short breast-feeding timeframe and rising prevalence of obesity in women after menopause will drive the industry size. Increasing rate of alcohol consumption in women, rising use of hormone replacement therapy (HRT) and oral birth control pills resulting in increased levels of oestrogen will boost the business size over the forecast period. Growing exposure to certain carcinogens and endocrine disruptors, for example in the workplace, working night shifts results in increased risk are surging up the U.S. market

Prohibitive cost associated with the use of breast cancer therapeutics may hamper the industry growth. Increasing cost of early and late-stage disease therapy, continuing care on a per-unit time basis, accounting for the major share of lifetime cost owing to relatively extended survival of breast cancer patients may further restrain the business growth